[go: up one dir, main page]

IL149364A0 - Hydroxamic acid derivative as inhibitor of the formation of soluble human cd23 - Google Patents

Hydroxamic acid derivative as inhibitor of the formation of soluble human cd23

Info

Publication number
IL149364A0
IL149364A0 IL14936400A IL14936400A IL149364A0 IL 149364 A0 IL149364 A0 IL 149364A0 IL 14936400 A IL14936400 A IL 14936400A IL 14936400 A IL14936400 A IL 14936400A IL 149364 A0 IL149364 A0 IL 149364A0
Authority
IL
Israel
Prior art keywords
inhibitor
formation
acid derivative
hydroxamic acid
soluble human
Prior art date
Application number
IL14936400A
Other languages
English (en)
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of IL149364A0 publication Critical patent/IL149364A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
IL14936400A 1999-10-27 2000-10-25 Hydroxamic acid derivative as inhibitor of the formation of soluble human cd23 IL149364A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9925470.8A GB9925470D0 (en) 1999-10-27 1999-10-27 Novel compounds
PCT/EP2000/010649 WO2001030747A1 (en) 1999-10-27 2000-10-25 Hydroxamic acid derivative as inhibitor of the formation of soluble human cd23

Publications (1)

Publication Number Publication Date
IL149364A0 true IL149364A0 (en) 2002-11-10

Family

ID=10863507

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14936400A IL149364A0 (en) 1999-10-27 2000-10-25 Hydroxamic acid derivative as inhibitor of the formation of soluble human cd23

Country Status (32)

Country Link
US (2) US6673965B1 (ja)
EP (1) EP1224164B1 (ja)
JP (1) JP3922431B2 (ja)
KR (1) KR20020044578A (ja)
CN (1) CN1182107C (ja)
AR (1) AR026244A1 (ja)
AT (1) ATE284382T1 (ja)
AU (1) AU766072B2 (ja)
BR (1) BR0015082A (ja)
CA (1) CA2389319A1 (ja)
CO (1) CO5261576A1 (ja)
CZ (1) CZ20021424A3 (ja)
DE (1) DE60016622T2 (ja)
DK (1) DK1224164T3 (ja)
ES (1) ES2233474T3 (ja)
GB (1) GB9925470D0 (ja)
GC (1) GC0000142A (ja)
HK (1) HK1049146A1 (ja)
HU (1) HUP0203270A3 (ja)
IL (1) IL149364A0 (ja)
MX (1) MXPA02004228A (ja)
MY (1) MY133601A (ja)
NO (1) NO20021965L (ja)
NZ (1) NZ518566A (ja)
PE (1) PE20010898A1 (ja)
PL (1) PL356524A1 (ja)
PT (1) PT1224164E (ja)
SI (1) SI1224164T1 (ja)
TW (1) TW561141B (ja)
UY (1) UY26416A1 (ja)
WO (1) WO2001030747A1 (ja)
ZA (1) ZA200203255B (ja)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5524215B2 (ja) 2008-09-19 2014-06-18 ファイザー・インク 抗菌剤として有用なヒドロキサム酸誘導体
EP2507266B1 (en) 2009-12-01 2015-02-18 Boston Medical Center Corporation TREATMENT OF IgE-MEDIATED DISEASE
PT2512474E (pt) 2009-12-16 2014-12-23 Pfizer Derivados de ácido hidroxâmico n-ligado úteis como agentes antibacterianos
CN104529883A (zh) 2011-03-07 2015-04-22 辉瑞大药厂 可用作抗菌剂的氟吡啶酮衍生物
WO2012137094A1 (en) 2011-04-08 2012-10-11 Pfizer Inc. Isoxazole derivatives useful as antibacterial agents
MX2013011432A (es) 2011-04-08 2013-12-09 Pfizer Derivados de imidazol, pirazol, y triazol utiles como agentes antibacterianos.
EP2525213A1 (en) * 2011-05-16 2012-11-21 Renishaw plc Spectroscopic apparatus and methods for determining components present in a sample

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9513331D0 (en) 1995-06-30 1995-09-06 British Biotech Pharm Matrix metalloproteinase inhibitors
GB9813451D0 (en) * 1998-06-22 1998-08-19 Smithkline Beecham Plc Novel compounds

Also Published As

Publication number Publication date
AU1389501A (en) 2001-05-08
UY26416A1 (es) 2001-05-31
US6673965B1 (en) 2004-01-06
TW561141B (en) 2003-11-11
CO5261576A1 (es) 2003-03-31
MXPA02004228A (es) 2002-10-17
GC0000142A (en) 2005-06-29
PT1224164E (pt) 2005-04-29
MY133601A (en) 2007-11-30
ES2233474T3 (es) 2005-06-16
HK1049146A1 (en) 2003-05-02
PL356524A1 (en) 2004-06-28
CA2389319A1 (en) 2001-05-03
US20040077727A1 (en) 2004-04-22
NO20021965L (no) 2002-06-13
HUP0203270A2 (hu) 2003-02-28
DE60016622D1 (de) 2005-01-13
DE60016622T2 (de) 2005-11-03
EP1224164A1 (en) 2002-07-24
WO2001030747A1 (en) 2001-05-03
NZ518566A (en) 2004-02-27
AR026244A1 (es) 2003-02-05
JP3922431B2 (ja) 2007-05-30
BR0015082A (pt) 2003-04-15
DK1224164T3 (da) 2005-03-29
GB9925470D0 (en) 1999-12-29
JP2003512450A (ja) 2003-04-02
CZ20021424A3 (cs) 2002-09-11
ZA200203255B (en) 2003-03-20
HUP0203270A3 (en) 2003-11-28
CN1182107C (zh) 2004-12-29
PE20010898A1 (es) 2001-10-13
AU766072B2 (en) 2003-10-09
CN1411436A (zh) 2003-04-16
ATE284382T1 (de) 2004-12-15
EP1224164B1 (en) 2004-12-08
KR20020044578A (ko) 2002-06-15
SI1224164T1 (en) 2005-06-30
NO20021965D0 (no) 2002-04-25

Similar Documents

Publication Publication Date Title
PL335027A1 (en) Derivatives of arylsulphonylamino hydroxamic acid
HUP0101793A3 (en) Anthranilic acid derivatives as inhibitors of the cgmp-phosphodiesterase
HK1049660A1 (en) Sulfamato hydroxamic acid metalloprotease inhibitor
IL148670A0 (en) Indolyl-3-glyoxylic acid derivatives comprising therapeutically valuable properties
IL147216A0 (en) Arylsulfonamido-substituted hydroxamic acid derivatives
AU2002220735A1 (en) Substituted derivatives of aminofuran-2-yl-acetic acid and aminothien-2-yl-acetic acid and the use thereof for treating migraines and pain
IL149364A0 (en) Hydroxamic acid derivative as inhibitor of the formation of soluble human cd23
HUP0103788A3 (en) Processes for the preparation of 5-hydroxy-3-oxopentanoic acid derivatives
AU7445100A (en) Sebum production inhibitors
HK1045260B (zh) 15-羥基二十碳四烯酸雜原子阻斷類似物及其使用方法
GB9929979D0 (en) Hydroxamic acid derivatives
GB2355657B (en) Inhibitors Of Gastric Acid Secretion
HK1025894A1 (en) Hydroxamic acid derivatives as inhibitors of the production of human cd23 and of the tnf release.
AU7653600A (en) Use of substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives for the treatment of multiple sclerosis
GB9907082D0 (en) The preparation of carboxylic acid derivatives
AU4021700A (en) Methods of use of beta1-integrin inhibitors
AU4332900A (en) Use of interleukin-11 to treat gastrointestinal disorders
AU2002218512A1 (en) Compound of hydroxamic acid derivative and hyaluronic acid
AU2001289723A1 (en) Novel use of difluoromalonic acid esters
AU1872001A (en) Hydroxamic acid derivatives as inhibitors of human cd23 and of the tnf release
AU7951600A (en) Anthranilic acid derivatives as inhibitors of the cgmp-phosphodiesterase
GB0026133D0 (en) Hydroxamic acid derivatives
PL332532A1 (en) Method of obatining 4-amino-5-hexenic acid
GB0109554D0 (en) Hydroxamic acid derivatives
GB0109553D0 (en) Hydroxamic acid derivatives